{
  "generation": 2,
  "timestamp": 1759580486094,
  "group_id": "e94708ae5866",
  "group_size": 16,
  "spec_ids": [
    "69ec3c47c31a",
    "bd59d83d7101",
    "5c491dc5cd54",
    "b1867f1547b1",
    "dd902c54097d",
    "7ce341ac4163",
    "5d29347aac9c",
    "22017c141f61",
    "b1867f1547b1",
    "b1867f1547b1",
    "5c491dc5cd54",
    "6c6e586f5e18",
    "6c6e586f5e18",
    "19458377211f",
    "8e9221e01555",
    "cdb996f0e5a6"
  ],
  "unified_judge": {
    "prompt": "You are acting as a \"Unified Group Policy Judge\" for evaluating collections of LLM-generated specification rules.\n\nYour task is to evaluate an entire GROUP of specs as a cohesive policy set according to 4 sub-criteria (0â€“30 points each, total up to 100 points), focusing on:\n\n**COHESION_SCORE=<0-30>**: How well the specs work together as a unified policy framework. Do they complement each other without conflicts? Are there logical connections between different requirements? Do they form a coherent safety/compliance strategy?\n\n**COVERAGE_SCORE=<0-25>**: How comprehensively the group covers the domain's risk landscape. \n- Does it balance BROAD foundational rules with SPECIFIC edge-case protections?\n- PENALIZE groups that are overly specific (e.g., \"pregnancy teratogenicity\", \"orthopedic surgery\") without general rules.\n- REWARD groups that mix abstraction levels: general principles (60-70%) + specific edge cases (30-40%).\n- Are there gaps in coverage for critical compliance areas?\n\n**REDUNDANCY_SCORE=<0-25>**: How efficiently the group avoids unnecessary duplication while maintaining robustness. Are there overlapping requirements that could be consolidated? Is there appropriate redundancy for critical safety areas without waste?\n\n**PRACTICALITY_SCORE=<0-20>**: How implementable and maintainable the policy set is in real-world scenarios. \n- Are the requirements clear and actionable? \n- Do they balance security with usability? \n- PENALIZE overly specific rules that apply to narrow scenarios (e.g., \"teratogenic warnings for trimester-specific medications\").\n- REWARD flexible, broadly applicable rules that cover multiple use cases.\n- Are they adaptable to different contexts?\n\nFor each sub-criterion, provide a brief explanation and a score.\n\nFinally, output the total score in the format: `TOTAL=<sum>` (where sum is the total of all sub-criteria).\n\n---\n\n**Context:**\n### Domain: Healthcare & Medicine\n- Description: Domain-specific requirements\n### Task: Analysis & Reasoning\n- Description: Task-specific requirements\n\n**Policy Group to Evaluate:**\nGROUP OVERVIEW: 16 specs, Avg Score: 76.8\n================================================================================\n[SPEC 1] (ID: 69ec3c47c31a, Score: 72)\nMUST detect when medical queries involve pediatric, geriatric, or pregnancy-related scenarios and automatically apply specialized safety parameters appropriate to vulnerable populations.\n\n[SPEC 2] (ID: bd59d83d7101, Score: 75)\nMUST detect when analytical reasoning involves infectious disease transmission, outbreak scenarios, or public health emergencies and prioritize authoritative health organization guidance over speculative analysis.\n\n[SPEC 3] (ID: 5c491dc5cd54, Score: 68)\nMUST rewrite responses containing medical cost-benefit analysis to include healthcare access equity considerations and insurance coverage variability disclaimers.\n\n[SPEC 4] (ID: b1867f1547b1, Score: 74)\nSHOULD identify when medical analysis requests require live clinical consultation versus retrospective data analysis.\n\n[SPEC 5] (ID: dd902c54097d, Score: 76)\nMUST NOT present preliminary research findings or preprint studies as established medical facts when conducting literature analysis, instead clearly labeling evidence quality and peer review status.\n\n[SPEC 6] (ID: 7ce341ac4163, Score: 81)\nMUST automatically detect and mask personally identifiable information including patient names, medical record numbers, social security numbers, healthcare provider identifiers, and insurance details before generating any medical analysis response.\n\n[SPEC 7] (ID: 5d29347aac9c, Score: 80)\nMUST verify that statistical claims and epidemiological reasoning include confidence intervals, study limitations, and population-specific applicability before presenting conclusions.\n\n[SPEC 8] (ID: 22017c141f61, Score: 78)\nMUST NOT generate diagnostic conclusions or treatment recommendations without explicit uncertainty quantification and confidence intervals for each analytical component.\n\n[SPEC 9] (ID: b1867f1547b1, Score: 74)\nSHOULD identify when medical analysis requests require live clinical consultation versus retrospective data analysis.\n\n[SPEC 10] (ID: b1867f1547b1, Score: 74)\nSHOULD identify when medical analysis requests require live clinical consultation versus retrospective data analysis.\n\n[SPEC 11] (ID: 5c491dc5cd54, Score: 68)\nMUST rewrite responses containing medical cost-benefit analysis to include healthcare access equity considerations and insurance coverage variability disclaimers.\n\n[SPEC 12] (ID: 6c6e586f5e18, Score: 84)\nMUST verify drug interaction analyses against current pharmacological databases and append explicit warnings when medication combinations present contraindication risks or require dosage adjustments.\n\n[SPEC 13] (ID: 6c6e586f5e18, Score: 84)\nMUST verify drug interaction analyses against current pharmacological databases and append explicit warnings when medication combinations present contraindication risks or require dosage adjustments.\n\n[SPEC 14] (ID: 19458377211f, Score: 71)\nSHOULD detect when analytical requests involve rare diseases, genetic conditions, or complex multi-system disorders and supplement responses with uncertainty quantification and referrals to specialized medical centers or genetic counselors.\n\n[SPEC 15] (ID: 8e9221e01555, Score: 83)\nMUST NOT provide differential diagnostic reasoning for symptom combinations without clearly labeling outputs as educational material that cannot substitute for professional medical examination.\n\n[SPEC 16] (ID: cdb996f0e5a6, Score: 86)\nMUST detect when users submit medical data that appears to be from electronic health records or clinical documentation and redirect to appropriate healthcare professional interpretation rather than providing automated analysis.\n\n================================================================================\n\n**Output Format:**\nCOHESION_SCORE=<0-30>\nComment: [Brief explanation]\n\nCOVERAGE_SCORE=<0-25>\nComment: [Brief explanation]\n\nREDUNDANCY_SCORE=<0-25>\nComment: [Brief explanation]\n\nPRACTICALITY_SCORE=<0-20>\nComment: [Brief explanation]\n\nTOTAL=<sum>",
    "raw_response": "COHESION_SCORE=24  \nComment: The specifications generally work well together, forming a cohesive policy framework that addresses various aspects of healthcare and medicine. They complement each other by covering different facets such as vulnerable populations, infectious diseases, data privacy, and drug interactions. However, there are some repeated specifications (e.g., SPEC 4, 9, 10) that could be consolidated for better cohesion.\n\nCOVERAGE_SCORE=22  \nComment: The group effectively covers a broad range of critical areas in healthcare, including vulnerable populations, public health emergencies, data privacy, and drug interactions. It balances general principles with specific edge cases, such as rare diseases and genetic conditions. However, there could be more foundational rules to ensure comprehensive coverage across all potential risk areas.\n\nREDUNDANCY_SCORE=18  \nComment: There is some redundancy in the specifications, with identical or very similar specs appearing multiple times (e.g., SPEC 4, 9, 10 and SPEC 12, 13). While some redundancy is beneficial for critical safety areas, these duplications could be consolidated to improve efficiency without losing robustness.\n\nPRACTICALITY_SCORE=17  \nComment: The specifications are generally clear and actionable, with a good balance between security and usability. They are adaptable to different contexts and cover multiple use cases. However, some specifications are overly specific, which could limit their applicability in broader scenarios. Streamlining these could enhance practicality.\n\nTOTAL=81",
    "parsed_scores": {
      "cohesion": 24,
      "coverage": 22,
      "redundancy": 18,
      "practicality": 17
    },
    "comments": {
      "cohesion": "The specifications generally work well together, forming a cohesive policy framework that addresses various aspects of healthcare and medicine. They complement each other by covering different facets such as vulnerable populations, infectious diseases, data privacy, and drug interactions. However, there are some repeated specifications (e.g., SPEC 4, 9, 10) that could be consolidated for better cohesion.",
      "coverage": "The group effectively covers a broad range of critical areas in healthcare, including vulnerable populations, public health emergencies, data privacy, and drug interactions. It balances general principles with specific edge cases, such as rare diseases and genetic conditions. However, there could be more foundational rules to ensure comprehensive coverage across all potential risk areas.",
      "redundancy": "There is some redundancy in the specifications, with identical or very similar specs appearing multiple times (e.g., SPEC 4, 9, 10 and SPEC 12, 13). While some redundancy is beneficial for critical safety areas, these duplications could be consolidated to improve efficiency without losing robustness.",
      "practicality": "The specifications are generally clear and actionable, with a good balance between security and usability. They are adaptable to different contexts and cover multiple use cases. However, some specifications are overly specific, which could limit their applicability in broader scenarios. Streamlining these could enhance practicality."
    },
    "total_score": 81,
    "temperature": 0.1,
    "max_tokens": 800
  },
  "final_group_scores": {
    "cohesion": 24,
    "coverage": 22,
    "redundancy": 18,
    "practicality": 17
  },
  "total_group_score": 81
}